+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Human Antimicrobial Susceptibility Testing Market by Type, Product, Method, Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674531
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Human Antimicrobial Susceptibility Testing Market grew from USD 3.71 billion in 2023 to USD 3.92 billion in 2024. It is expected to continue growing at a CAGR of 5.88%, reaching USD 5.54 billion by 2030.

Human Antimicrobial Susceptibility Testing (AST) involves determining the effectiveness of antibiotics against specific bacteria, a crucial process in combating the rising challenge of antibiotic resistance. It plays a pivotal role in ensuring effective treatment regimens, guiding healthcare professionals in selecting appropriate antibiotics. The necessity of AST is driven by the alarming increase in resistant bacterial strains, making accurate and timely susceptibility testing essential for patient safety and public health management. Applied primarily in clinical settings and laboratories, AST supports pharmaceutical research and epidemiology studies, serving end-use sectors such as hospitals, clinics, research institutions, and diagnostic laboratories. The market for AST is being propelled by advances in technology, growing awareness of antimicrobial resistance, and the increasing prevalence of infectious diseases. Developments in rapid testing methods, such as automated and molecular-based techniques, offer notable opportunities for market growth by enhancing testing speed and accuracy. Regulatory support and funding for research aim to address these critical health threats, further encouraging market expansion. However, the high cost of advanced testing, technical complexity, and limited accessibility in lower-income regions pose significant challenges. The market's potential is hindered by these limitations alongside concerns over standardization and validation of new testing methods. Innovative opportunities lie in developing cost-effective, high-throughput testing technologies and integrating artificial intelligence for enhanced data analysis and prediction capabilities. Collaborative research initiatives across public and private sectors can drive breakthroughs in AST methods and technologies. The market, characterized by its rapid evolution and intense competition, demands constant innovation, adaptability, and strategic partnerships to thrive. For businesses, investing in R&D to foster affordable and reliable testing solutions, expanding digital platforms for data sharing, and enhancing global distribution networks are recommended strategies to capitalize on the market's potential and overcome existing challenges.

Understanding Market Dynamics in the Human Antimicrobial Susceptibility Testing Market

The Human Antimicrobial Susceptibility Testing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of infectious diseases due to the rising pathogens
    • Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
    • Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
  • Market Restraints
    • High cost of automated antimicrobial susceptibility testing
  • Market Opportunities
    • Technological advancements towards the development of rapid human AST methods
    • Increasing funding, research grants, and public-private investments in the market
  • Market Challenges
    • Complex regulatory frameworks coupled with issues in testing in developing countries

Exploring Porter’s Five Forces for the Human Antimicrobial Susceptibility Testing Market

Porter’s Five Forces framework further strengthens the insights of the Human Antimicrobial Susceptibility Testing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Human Antimicrobial Susceptibility Testing Market

External macro-environmental factors deeply influence the performance of the Human Antimicrobial Susceptibility Testing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Human Antimicrobial Susceptibility Testing Market

The Human Antimicrobial Susceptibility Testing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Human Antimicrobial Susceptibility Testing Market

The Human Antimicrobial Susceptibility Testing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Human Antimicrobial Susceptibility Testing Market

The Human Antimicrobial Susceptibility Testing Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE TIBBI MALZ, BioMérieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, ELITech Group SAS, Erba Lachema s.r.o., F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Liofilchem S.r.l., Mast Group Ltd., Merck KGaA, Pfizer Inc., Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Antibacterial Susceptibility Testing
    • Antifungal Susceptibility Testing
    • Antiparasitic Susceptibility Testing
  • Product
    • Automated Laboratory Instruments
    • Consumables
    • Culture & Growth Media
    • Manual Antimicrobial Susceptibility Testing Products
  • Method
    • Agar Dilution
    • Automated Susceptibility Testing Instruments
    • Disk Diffusion
    • Etest Method
    • Genotyping Methods
  • Application
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Epidemiology
  • End User
    • Contract Research Organizations
    • Hospital & Diagnostic Centers
    • Pharmaceutical & Biotechnology
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of infectious diseases due to the rising pathogens
5.1.1.2. Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
5.1.1.3. Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
5.1.2. Restraints
5.1.2.1. High cost of automated antimicrobial susceptibility testing
5.1.3. Opportunities
5.1.3.1. Technological advancements towards the development of rapid human AST methods
5.1.3.2. Increasing funding, research grants, and public-private investments in the market
5.1.4. Challenges
5.1.4.1. Complex regulatory frameworks coupled with issues in testing in developing countries
5.2. Market Segmentation Analysis
5.2.1. Type: Rising R&D investment to develop next generation susceptibility testing
5.2.2. End User: Rising demand across hospital & diagnostic centers to guide patient-specific treatment strategies
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Human Antimicrobial Susceptibility Testing Market, by Type
6.1. Introduction
6.2. Antibacterial Susceptibility Testing
6.3. Antifungal Susceptibility Testing
6.4. Antiparasitic Susceptibility Testing
7. Human Antimicrobial Susceptibility Testing Market, by Product
7.1. Introduction
7.2. Automated Laboratory Instruments
7.3. Consumables
7.4. Culture & Growth Media
7.5. Manual Antimicrobial Susceptibility Testing Products
8. Human Antimicrobial Susceptibility Testing Market, by Method
8.1. Introduction
8.2. Agar Dilution
8.3. Automated Susceptibility Testing Instruments
8.4. Disk Diffusion
8.5. Etest Method
8.6. Genotyping Methods
9. Human Antimicrobial Susceptibility Testing Market, by Application
9.1. Introduction
9.2. Clinical Diagnostics
9.3. Drug Discovery & Development
9.4. Epidemiology
10. Human Antimicrobial Susceptibility Testing Market, by End User
10.1. Introduction
10.2. Contract Research Organizations
10.3. Hospital & Diagnostic Centers
10.4. Pharmaceutical & Biotechnology
10.5. Research & Academic Institutes
11. Americas Human Antimicrobial Susceptibility Testing Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Human Antimicrobial Susceptibility Testing Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Human Antimicrobial Susceptibility Testing Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Strategic Investment in Rapid Diagnostic Technologies by CARB-X to Combat Antibiotic-Resistant Gonorrhea and Enhance Global STI Management
14.3.2. Microplate Secures Funding for Innovation in Combatting Antimicrobial Resistance
14.3.3. Introducing Sysmex's Rapid Antimicrobial Susceptibility Testing System
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET RESEARCH PROCESS
FIGURE 2. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET DYNAMICS
TABLE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED LABORATORY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CULTURE & GROWTH MEDIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SUSCEPTIBILITY TESTING INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPING METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITAL & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 49. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 50. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 55. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 77. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 81. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 82. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 92. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 122. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 138. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 142. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 143. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 147. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 148. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 152. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 153. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 157. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 158. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 168. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 182. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 183. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 187. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 188. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 192. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 193. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 212. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 213. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 227. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 228. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 241. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Human Antimicrobial Susceptibility Testing market, which are profiled in this report, include:
  • Alifax S.r.l.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BIOANALYSE TIBBI MALZ
  • BioMérieux SA
  • Biosafe Ltd.
  • Bruker Corporation
  • Creative Diagnostics
  • ELITech Group SAS
  • Erba Lachema s.r.o.
  • F. Hoffmann-La Roche AG
  • Genefluidics, Inc.
  • Himedia Laboratories Private Limited
  • INTEGRA Biosciences AG
  • Laboratorios Conda, S.A.
  • Launch Diagnostics Limited
  • Liofilchem S.r.l.
  • Mast Group Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc.
  • Zhuhai DL Biotech Co., Ltd.

Methodology

Loading
LOADING...

Table Information